✦ LIBER ✦

Activity of pirarubicin (4′-o-tetrahydropyranyladriamycin) in malignant mesothelioma

✍ Scribed by Kasi S. Sridhar; Atif M. Hussein; Lynn G. Feun; C. Gordon Zubrod

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 756 KB
Volume: 63
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19890315)63:6<1084::aid-cncr2820630608>3.0.co;2-u

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of 4′-O-tetrahydropyranyl

Phase II trial of 4′-O-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma

✍ Kasi S. Sridhar; Atif M. Hussein; Pasquale Benedetto; Bach Ardalan; Niramol Sava 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 695 KB

## Background. 4'-O-tetrahydropyranyladriamycin (Pirarubicin, Meiji Seika (USA) Inc., New York, NY) may be less toxic than doxorubicin. A Phase I1 trial of Pirarubicin was done in 26 patients who had not previously had chemotherapy and who had measurable and incurable head and neck carcinoma. All

A phase II study of pirarubicin in malig

A phase II study of pirarubicin in malignant pleural mesothelioma

✍ E. Kaukel; G. Koschel; U. Gatzemeyer; E. Salewski 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 396 KB 👁 3 views

Treatment of acute leukemia and malignan

Treatment of acute leukemia and malignant lymphoma with (2″R)-4′-O-tetrahydropyranyladriamycin

✍ Ryuzo Ohno; Kiyoji Kimura; Ichita Amaki; Masami Hirano; Akira Hoshino; Yasushi I 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 522 KB

(2″-R)-4′-o-Tetrahydropyranyladriamycin,

(2″-R)-4′-o-Tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies

✍ Toshiyuki Takagi; Masao Oguro 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 349 KB

Thirty-eight patients with adult acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL) were treated intravenously with (2"-R)-4'-o-Tetrahydropyranyladriamycin (THP) at a dose of 10 mg/m2 for 5 consecutive days. Seven complete and 15 partial responses were observed in 35 evaluable patien

Activity of intrapleural recombinant gam

Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma

✍ C. Boutin; J. R. Viallat; N. van Zandwijk; J. T. Douillard; J. C. Paillard; J. C 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 506 KB

A phase II study of (2″ R)-4′ -0-tetrahy

A phase II study of (2″ R)-4′ -0-tetrahydropyranyladriamycin (THP) in hematological malignancies

✍ Kazumasa Yamada; Shigeru Shirakawa; Ryuzo Ohno; Hideo Yamada; Yutaka Hirota; Kan 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 441 KB

A phase II study of new anthracycline, THP, was conducted in 46 patients with hematological malignancies in a cooperative study. THP was given intravenously either at a dose of 13-34 mg/m 2 for 3-5 consecutive days or 35-50 mg/m 2 at 3-4 week intervals. Of 21 patients with acute leukemia, complete